Compugen Ltd (NASDAQ:CGEN) CEO Anat Cohen-Dayag tells Proactive's Stephen Gunnion about the drug discovery and development company focused on cancer immunotherapy using the predictive power of its unique computational discovery approach.
Cohen-Dayag explains that Compugen is advancing new therapeutics and optimizing their combination to expand immuno-oncology treatment options to cancer patients who are refractory or unresponsive to currently available drugs.
"There is great potential for a company that brings first-in-class drug opportunities to treat patients, however when you are pioneering the field, the burden of proof is on you and that is challenging," she says.